Dr. Suzana Voiculescu

Similar documents
Coagulation Mechanisms Dr. Nervana Bayoumy

Sign up to receive ATOTW weekly -

Hemostasis and Thrombosis

Adv Pathophysiology Unit 4 Page 1 of 10. Learning Objectives for this file:

Hemostasis. by Mohie-Aldien Elsayed

Introduction Hemostasis: Tourniquet Test & Bleeding Time. Hematology-Immunology System Faculty of Medicine Universitas Padjadjaran LOGO

BLOOD COAGULATION. 1. The initial phase of the process is vascular constriction. This limits the flow of blood to the area of injury.

Physiology Unit 3 HEMATOLOGY

These handouts are only meant as a guide while you follow the presentation on the screen. Sometimes the speaker will change some of the slides.

General Principles of. Hemostasis. Kristine Krafts, M.D.

Local vasoconstriction. is due to local spasm of the smooth muscle (symp. reflex) can be maintained by platelet vasoconstrictors

Special Coagulation - APC Resistance. DiaPharma Group, Inc. Customer Service: Technical Support:

Coagulation Cascade. TF-VIIa. Tissue Factor + VII. XIIa. Prothrombin. XIa. IXa. VIIIa. Thrombin. XL- Fibrin. XIII Monomer. Fibrinogen.

COAGULATION: BASIC PRINCIPLES. Peyman Eshghi Prof. of Pediatric Hematology & Oncology

Methods of Biomaterials Testing. Special Biology: Blood & Vessel

2013 Health Press Ltd.

Chapter 19b Blood, cont d

Department of medical physiology 3 rd week

LABORATORY DIAGNOSIS OF BLEEDING DISORDERS

Using TEG in the ED, OR, and ICU. Don H. Van Boerum, MD, FACS

Enzyme Research Laboratories product list 2018

LABORATORY APPROACH TO BLEEDING DISORDERS DR NISHANTH PG 1 ST YEAR DEPARTMENT OF PATHOLOGY

Ch 13: Blood. What does blood do? Transport: Regulation: Protection:

HaematologY. Dr Tom Bate Again!

The Coagulation Workup In The Office Setting

CHROMOGENIC SUBSTRATE TECHNOLOGY. Giovanni Russi

Laboratory investigation in the Bleeding Patient. Dr Craig Taylor Consultant Haematologist May 2016

Haemostasis. The function of haemostasis is: to prevent blood loss from injured vessels. to stop bleeding. to prevent thrombosis

The Cardiovascular System: Blood

Overview of Anatomy and Physioloy II Second Year Students

Common Inherited Bleeding Disorders

Plasma Testing in the Clinical Coagulation Laboratory: New drugs, new problems.

Basic coagulation applications and case studies

Evolution of the Clotting Cascade. Kalyan Banda MD Hematology Fellows Conference 01/13/2017

Rheological Properties of Fibrin Clots

Primary hemostasis. Vascular endothelium Vasoconstriction : local tissue factor, nervous system

Case 1. Case 1. Case 2. Case 2. Review of Bleeding Disorders Case 1

Coagulation in perspective: Blood management. Objectives

proteins. The ECs are supported by a collagen-rich

Biochemistry of connective tissue Pathochemistry of inflammation

Rheological and biochemical analyses on blood coagulation ~ Discovery of a new pathway under stagnant flow conditions ~

The Role Of Point of Care Coagulation Testing (POCCT) in Patient Blood Management. Elham Khalaf Adeli

Immunomodulation at Cardiac Surgery. William T McBride MD

The COAGULATION CASCADE:

Pharmacology Lecture 5. Anticoagulants

Laboratory Investigation of Challenging Cases. Laura A. Worfolk, Ph.D Scientific Director, Coagulation

*NCCT is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. Program, provider #122.

Acute Traumatic Coagulopathy

Cell-Extracellular Matrix Interactions

Veins Valves prevent engorgement and backflow. Baroreceptor reflex. Veins returning blood

Haemostasis Reagents product list 2018

Session 1 Topics. Vascular Phase of Hemostasis. Coagulation Pathway. Action of Unfractionated Heparin. Laboratory Monitoring of Anticoagulant Therapy

Common Inherited Coagulation Disorders. Inherited Coagulation Disorders. All coagulation factors and platelets in circulation (unactivated)

Evaluation of Complex Coagulation Cases: Case-Based Illustrations of Important Issues

Veins Valves prevent engorgement and backflow. Baroreceptor reflex. Veins returning blood

Hypercoagulation. CP Conference 11/14/2006

Evaluation of the Bleeding Patient

Disclosures. I have received research funding from: I have received consulting fees/honoraria from: Novo Nordisk CSL-Behring Boehringer Ingelheim

The effects of hypothermia and acidosis on Haemostasis

THE PROCOAGULANT ROLE OF NUCLEIC ACIDS IN THE CONTACT SYSTEM

STRUCTURE-FUNCTION RELATIONSHIPS OF INTERSTITIAL TRANSPORT AND MECHANICS IN BLOOD CLOTS

Sysmex Educational Enhancement and Development No

Anticlotting mechanisms 1: physiology and pathology

Hemostasis practice: state-of-the-art

Hematology Emergencies: Problems with Platelets

A Novel Method for the Quantitative Evaluation of Fibrinogen Coagulation

Cardiovascular (connective tissue)

BNG 331 Cell-Tissue Material Interactions. Wound Healing I

Suitability of analytical methods for detection of thrombogenic factor XIa in Privigen

Coagulopathy Case-2. Andy Nguyen, M.D. 2009

BIOCHEMICAL STUDIES ON BLOOD COAGULATION MECHANISM EFFECT OF RECOMBINANT VON WILLEBRAND FACTOR A1 DOMAIN ON THE PROCESS OF HEMOSTASIS

Index. Autoimmune thrombocytopenic purpura (AITP), 100, 102, 105, 108, 187 Automated platelet counters, , 108

P. W. HOWIE M.D., M.R.C.O.G. first method of activation is the intrinsic system. Hageman factor, which in turn activates a series of

The Combined Use of Bypassing Agents with Antithrombin Reduction in Plasma of Hemophilia A and B Patients with Inhibitors

WFH 2014 World Congress Medical Free Paper 8 ALN AT3: An Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia

Inherited bleeding disorders: disorders of platelet adhesion and aggregation

Serine Proteases and their Inhibitors

Laboratory Investigation of Challenging Cases. Laura A. Worfolk, Ph.D Scientific Director, Coagulation

MAMMALIAN CELL SURFACE DISPLAY OF FUNCTIONAL ALPHA 1-PROTEASE INHIBITOR: BUILDING DESIGNER SERPINS RICHARD FRANK GIERCZAK

Drugs used in Thromboembolic Disease. Munir Gharaibeh, MD, PhD, MHPE Department of Pharmacology Faculty of Medicine October 2014

Transfusion & Non-transfusion Approaches to Bleeding

Coagulation. Coagulation Limited CGL, CGDF Surveys & Anatomic Pathology Education Programs. Coagulation 117

Lina Al-Lawama. Rama Al-Ashqar. Malik Al-Zohlof

Current laboratory practices in the diagnosis and management of haemophilia

Molecular Mechanism of Platelet Activation 제주대학교병원내과 주승재

Research Article Massive Exploration of Perturbed Conditions of the Blood Coagulation Cascade through GPU Parallelization

An Analysis of the Robustness and Fragility of the Coagulation System

THE EFFECT OF THAWING FRESH FROZEN PLASMA AT VARIOUS TEMPERATURES ON IN VITRO COAGULATION FACTOR ACTIVITY

Disclaimer: this is a very big topic and coverage will be only superficial.

Sysmex Educational Enhancement and Development No

Impact of Thrombomodulin and Thrombin- Activatable Fibrinolysis Inhibitor on the Anticoagulant and Profibrinolytic Effects of Rivaroxaban

Management of Bleeding in the Anticoagulated Patient Short Snappers CSIM 2015 Elizabeth Zed, MD, FRCPC October 17, 2015

HIBOR. 1st Prophilaxis. Acute phase treatment. Pentasaccharide. Long-term 2ª ACOs UFH LMWH LMWH LMWH. Competitors

Platelet type bleeding: (vwd) - Petechiae, purpura, ecchymoses, bruising - Menorrhagia, hematuria, occult GI bleed - Gingival bleeding, epistaxis

Factor Concentrates. More is better? Alexander Duncan MD Emory Medical Labs

De l'utilisation de la microscopie intravitale pour étudier la thrombose in vivo et tester de nouveaux médicaments antithrombotiques- 1er partie

POST-ISTH: Novità dal meeting di Toronto 2015 Piastrine: fisiopatologia. Erica De Candia Università Cattolica -Roma

2 Thomas G. DeLoughery

Inhibition of Plasmin Generation in Plasma by Heparin, Low Molecular Weight Heparin. and a Covalent Antithrombin-Heparin Complex (ATH)

Substrates of Factor XIII-A: roles in thrombosis and wound healing

Transcription:

Dr. Suzana Voiculescu

Overview of hemostasis Initiated when trauma, surgery or disease disrupts the vascular endothelium, exposing blood to the subendothelial connective tissue Achieved by: 1)Vasconstriction + collateral dilation 2)Formation of a platelet plug 3)Formation of a blood clot as a result of blood coagulation Secondary hemostasis Primary hemostasis

Vascular response to injury Local vasoconstriction: 1) local myogenic spasm -initiated by direct damage to the vascular wall 2) thromboxane A2 (TXA2) and serotonin release by activated platelets; endothelin-1(et-1) produced by the endothelium in response to thrombin 3)nervous reflexes-nociceptor reflex Compression of injured vessels by extravasation of blood into surrounding tissues Vasodilation of the collateral vessels- redirecting flow

Primary hemostasis In a normal individual, hemostasis is initiated within 20 seconds after an injury occurs to the blood vessel damaging the endothelial cells. Platelets immediately form a haemostatic plug at the site of injury. This is called primary hemostasis. This is the only phase in cappilaries

Plateles What is a platelet? Small 2-3 µm Anuclear Reddish-purple granules Fragments of megakaryocyte cytoplasm Life span 9-10 days Normal Range 150-400 x 10 9 /L

Thrombopoiesis - production in BM by fragmentation of megakariocytes - megakariocytes mature by endomitotic synchronous nuclear replication: no. of nuclear lobes increase in multiples of two together with enlargement of the cytoplasmic volume at variable stage in development (mature polyploid cell, ~ 8 nucleus stage), nuclear replication & cytoplasm growth cease

cytoplasm becomes granular (form. of microvesicles) platelets are released (~4,000 platelets/megakariocyte) - time interval from differentiation of the stem cell to the production of platelets (thrombocytopoiesis) ~ 10 days - control by thrombopoietin, IL-6, IL-3, Vit B12, GM-CSF (effects: in no. of megakariocytes and in mean volume or nuclear units)

Nuclear Cytoplasmic Platelets replication granulation

Platelet anatomy ext int Peripheral zone- glycocalix + membrane Sol gel zone Organelle zone

Peripheral zone Plasma membrane- normal lipid bilayer On the outer membrane- neutral PLphosphatidilcholine, sphingomyelin On the inner membrane- negative PL: Phosphatidilinositol supports platelet activation arachidonic acid eicosanoids PG+TxA2 (platelet activator + vasoconstrictor) Phosphatidilserine flips to the outer membrane when platelets get activated PL surface on which coagulation enzymes asemble

Peripheral zone Contains glycoprotein receptors: GP Ib-IX-V complex binds von Willebrand s factor needed for platelet adhesion to collagen GP Ia/IIa= ligand collagen GP IV= ligand collagen GP VI= ligand collagen GP Ic/IIa= ligand laminin and fibronectin GPIIb/IIIa binds fibrinogen needed for aggregation G- protein coupled receptor- P2Y12- for ADP Receptors for thrombin, epinephrine- platelet activators

Peripheral zone Glycocalix Platelet mb surface- adsorbs albumins, fibrinogen Thicker than other cells Negative charge- repels other cells (other platelets, other blood cells, endothelial cells) Surface connected canalicular system (SCCS)- plasma membrane invades interior- GP receptors and route for granule secretion upon platelet activation

Structural or Sol-Gel zone Beneath the peripheral zone Responsible for platelet retraction/contraction functions and platelet shape Maintainance of discoid shape (when inactive)- microtubules Contractile system- mainly actin, also myosin- upon activation- shape change, pseudopod extensions, internal contraction, granule release

Organelle zone Responsible for storage and platelet release functions Granules Dense bodies Alpha granules Lysosomes Mitochondria Glycogen Dense tubular system (DTS)- condensed RER- no proteic synthesis function, but Ca++ storage and enzymes (PLA2, COX, TxA2 synthetase, PLC)

Granules Dense (SAC)- Serotonin, ADP/ATP, Calcium Alpha adhesive proteins- fibrinogen, fibronectin, vwf growth promoting substances- PDGF, PF4, TGF Coagulation factors- V, HMWK, IX, plasminogen activator inhibitor-1

Activation Happens at the site of vascular injury PHYSIOLOGICAL ACTIVATORS THROMBIN ADP COLLAGEN EPINEPHRINE TXA2

Activation pathways

Thrombin dependent activation Mediated by G protein coupled protease activated receptors (PAR 1 and 4) Thrombin cleaves the external domain of PAR transmembranary signalling

Thrombin activation is mediated by G protein-coupled proteaseactivated receptor (PAR). Thrombin cleaves the NH2-terminal exodomain of the PAR, exposing a new NH2 terminus, which then serves as a tethered ligand to bind intramolecularly to the body of the receptor to initiate transmembrane signaling.

ADP dependent activation Requires the coordinated activation of two G protein coupled receptors P2Y1 and P2Y12 Ligand receptor binding G protein mediated signal PLA 2 activation TXA2 camp supression

Platelets activation factors

After platelets are activated, they undergo significant morphologic changes, producing elongated pseudopods. They also become extremely adhesive. The functional response of activated platelets involves four distinct processes: adhesion (deposition of platelets on subendothelial matrix); aggregation (cohesion of platelets); secretion (release of platelet granule proteins); and procoagulant activity (enhancement of thrombin generation).

Platelets activation and secretion 1. Cytoskeletal and morphological changes - formation of fingerlike pseudopodia+ presenting polar phospholipids on the surface (phosphatidilserine) 2. Prostaglandin Pathway- TXA2 formation from Arachidonic acid 3. Direct Granular Release contraction of actin and myosin SPPS exocitosis ADP and serotonin: stimulate and recruit additional platelets PDGF proliferation of smooth muscle cells and tissue repair Factor V: receptor on platelet surface for factor Xa & prothrombin initiation of coagulation 4. GPIIb/IIIa activation (heterodimer) platelet plug

Morphological changes

Eicosanoid pathway activation

Platelets adhesion In venules and veins (low shear rate)- TR adhere directly to collagen- GP Ia/IIa, GP IV, GP VI In capillaries and arterioles (shear rate high)- the site of the injury is first carpeted with vwf and platelet adhesion is primarily mediated by the binding of platelet surface receptor glycoprotein (GP) Ib/IX/V complex to the adhesive protein von Willebrand factor (vwf) bound to collagen Deficiency of Ib/IX/V: Bernard-Soulier syndrome AR

Von Willebrand factor Multimeric globulin Synthesis by endothelial cells + megacariocytes (it is found in the dense TR granules) 800 000-20 million Da Injury unrolls into fibrills and coats lesion (collagen) Functions Adhesion Stabilizes the procoagulant factor VIII (FVIII)

Von Willebrand disease Inherited bleeding disorder 3 types, depending on the severity of vwf deficit (type III is the most severe) 1,2- mild manageable bleeding only manifests in trauma/invasive procedures Acquired Very rare vwf antibodies- hypothyroidism

Why not adhere on normal endoth cells? Normally, endothelial cells exhibit antiplatelet, anticoagulant, and fibrinolytic properties. ANTIPLATELET Secrete NO and PGI2- inhibit TR adhesion and aggregation Produce ADPase- it degrades ADP (which is a powerful TR activator)

Aggregation Requires the active conformation of GPIIb/IIIa integrin Normally, it dimerizes due to ligand mediated platelet activation (inside-out signalling) Active GPIIb/IIIa binds fibrinogen

Platelets aggregation Chemical changes cause platelets to aggregate and stick to one another Newly arriving platelets become activated by agonists Exposure of GPIIb/IIIa sites bind fibrinogenfibrinogen bridges between TR= PLATELET PLUG

Interactions between activated TR and clotting cascade Activation of TR anionic lipids exposure on surface Factor V is released from TR granules binds in the phospholipids activation of fv Va Va acts as an assembly site for the binding of Xa (active enzyme) and prothrombin (substrate)= PROTHROMBINASE COMPLEX Platelet plug keeps thrombin localized Simillar enzyme complex assembly applies to the activation of X by VIIIa and IXa amplification COAGULATION PURPOSE- TURN FIBRINOGEN IN THE PLUG INTO FIBRIN CLOT

Secondary hemostasis= coagulation Composed of 14 coagulation factors (serine proteases) which are interdependent (Factors I through XIII there is no Factor VI plus PK and HMWK) Inactive form of each is an enzyme precursor which is usually designated by a Roman numeral but also given a name Ex. Factor I fibrinogen. Numbers correspond to order of discovery NOT order in cascade. Active forms are usually designated by the letter a after the Roman numeral and may also have a different name Ex. Ia Fibrin Cofactors are needed for many reactions in the cascade Ex. Calcium, membrane phospholipids

Secondary hemostasis Contact Activation pathway (Intrinsic Pathway) Tissue Factor pathway (Extrinsic pathway) It was previously thought that the coagulation cascade consisted of two pathways of equal importance joined to a common pathway. It is now known that the primary pathway for the initiation of blood coagulation is the Tissue Factor pathway. The pathways are a series of reactions, in which a zymogen (inactive enzyme precursor) of a serine protease and its glycoprotein co-factor are activated to become active components that then catalyze the next reaction in the cascade

Secondary hemostasis Coagulation proteins work in concert to generate prothrombin activator or prothrombinase (step 1) Prothrombinase acts on prothrombin, a plasma protein, to form thrombin (step 2) Thrombin converts fibrinogen to fibrin (step 3); fibrin consolidates the platelet plug made in primary hemostasis such that a fibrin clot (secondary hemostatic plug) is formed

INTRINSIC PATHWAY The contact activation pathway begins with formation of the primary complex on collagen by highmolecular-weight kininogen (HMWK), prekallikrein, and FXII (Hageman factor) FXII becomes FXIIa in contact with the negatively charged membrane; HMWK is an anchor Prekallikrein is converted to kallikrein- positive feed back on XII factor activation FXIIa converts FXI into FXIa.

Intrinsic pathway Factor XIa activates FIX into IXa Factor VIII is activated by thrombin Thrombin is activated downstream and has a positive feed back on the coagulation cascade!! FVIIIa + FIXa+ Ca ions + PL= tenase complex, which activates FX to FXa.

CLASSIC THEORY The contact of blood with the vascular endothelial collagen or with the surface of an activated platelet triggers the intrinsic pathway or contact phase of coagulation; the trigger is inside the vascular system The interaction of blood with material from damaged cell membranes (tissue factor) activates the extrinsic pathway or tissue factor dependent pathway; the trigger is outside the vascular system

PL PL

EXTRINSEC PATHWAY Following damage to the blood vessel, FVII leaves the circulation and comes into contact with tissue factor (TF) expressed on tissue-factor-bearing cells (stromal fibroblasts and leukocytes), forming an activated complex (TF-FVIIa). This takes place on the non-vascular surface TF-FVIIa + Ca ions = tenase like complex. activation of FX into Xa

Tissue factor Synonim- thromboplastin, factor III Expressed on the membrane of non-vascular cells After a vessel injury, it comes into contact with VII, seves as an anchor at the surface of the cells Activation on VII VIIa needs also Ca++ from TR granules

COMMON PATHWAY FXa + F Va+ PL + Ca ions= PROTHROMBINASE COMPLEX TURNES PROTHROMBIN INTO THROMBIN Thrombin acts on fibrinogen fibrin monomers fibrin (XIII factor stabilizes the clot)

Thrombin Thrombin primary role is the conversion of fibrinogen to fibrin monomers, the building block of a clot monomers polymerize spontaneusely Activates factor XIII XIIIa- it is found in the TR granules crosslinkage of fibrin polymers insoluble stable mesh of fibin Activates Factors VIII and V and their inhibitor protein C (in the presence of thrombomodulin)

Thrombin Positive feedback- following activation by the contact factor or tissue factor pathways, the coagulation cascade is maintained in a prothrombotic state by the continued activation of - IX -X -XI -XII

Thrombin Binds with thrombomodulin on endothelial cell surfaces to form a complex which activates protein C Stimulates endothelial cells to produce NO, PGI2, ADP, vwf, tissue plasmin activator Activates platelets Activates plasmin- fibrinolysis

Fibrinogen

Fibrinogen GP 3 paires of polypeptides Aa, Bb and Gg All 6 NH2- terminal ends toward the center (E domain) 2 globular ends (D domains) Thrombin- cleaves the N-terminal ends of Aa and Bb (known as fibrinopeptides A and B) fibrin monomer

Fibrin- polymers One E domain interacts with 4 D domains on other fibrin molecules Polymers crosslink due to XIIIa factor activity that cross- links glutamine residues on one fibrin molecule to the lys residues on another molecule (between C term ends- Aa protuberances)

Fibrin clot

Clot Fibrin mesh Thrombocytes Entrapped blood cells

Classic view- unanswered questions Is useful in blood test interpretation But it is not accurate- patients with a severe fxii deficit don t bleed initiation coagulation begins with the extrinsic pathway in vivo Generation/ exposure to tissue factor at the wound site, is the primary physiological event that initiates clotting Patients with VIII and IX dificits- very severe bleeding (TF- VIIa is inhibited by TFPI sustained activation of X via intrinsic pathway is critical for normal hemostasis)

Modern theory Initiation of coagulation VII to become VIIa F VIIa activates X directly/ indirectly via the activation of factor IX, dual pathway for fx activation- necessary because Limited amount of TF generated in vivo Presence of tissue factor pathway inhibitor (TFPI) when complexed with Xa inhibitis TF- VIIa complex (TFPI inhibits Xa and TF-VIIa complex)

Plasmatic factors Secreted in the liver, except for the vwf (endoth cell and megacariocytes) Vitamin K dependent procoagulants- prothrombin, VII, IX and X Vitamin K dependent anticoagulants- protein C and S

Cellular theory Initiation phase- TF complexed with VIIa initiates coagulation at the site of injury small amounts of thrombin are generated and activate platelets Amplification phase-coagulation factors form complexes on TR surfaces Propagation phase- very large amounts of thrombin are formed to convert fibrinogen to fibrin which reinforces platelet plug

Initiation phase

Amplification phase

Propagation phase

Clot retraction The end process Fibrin fibres are attached to damaged blood wall Clot begins to contract by using the contractile apparatus of the TR Clot si more tight and stable In the process- the liquid that is expressed= serum (lacks most of the coagulation factors)

Clotting regulation Dillution of procoagulants in flowing blood Removal if activated factors through reticuloendothelial system (liver mostly) Antithrombotic natural pathways- 7 systems Antithrombin III Protein C Protein S Tissue factor pathway inhibitos (TFPI) Prostacyclin and NO- modulate vascular and platelet reactivity ADP-ase- inhibits platelet recruitment Fibrinolysis- removes the clot

ATIII- heparan sulfate system ATIII- circulating plasma protease inhibitor Inhibits thrombin and fxa- key enzymes inhibits XIIa and Xia activated by heparan sulfate on the surface of the endoth cells- binds to a site on ATIII- conformational change thrombin instant and irreversable inhibition But... endoth cells are coated with already active ATIII!basis for the therapeutic use of heparin

Protein C/S/thrombomodulin system Thrombomodulin- integral protein on the luminal surface of the endoth Thrombin binds to thrombomodulin thrombin inactivates and it activates protein C in plasma Protein S is a cofactor for protein C activation Activated protein C inhibits Va and VIIIa

Tissue factor pathway inhibitor (TFPI) Circulating plasma protease inhibitor synth by endothelium Very low plasma concentrations Inhibits Xa TFPI-Xa factor complex inhibits TF/VIIa complex TFPI depletion disseminated intravascular coagulation (CID)

Von Willebrand s disease the most common hereditary coagulation abnormality qualitative or quantitative deficiency of von Willebrand factor (vwf) Defective platelet adhesion Varying degrees of bleeding Types Hereditary- most common Aquired- autoantibodies Platelet type- inherited (affects receptors in platelets)

Hemophilia group of hereditary genetic disorders that impair the body's ability to control blood clotting or coagulation Excessive bleeding, minor injury Sex- linked Type A- VIII factor deficit Type B- IX factor deficit Not sex- linked Type C- XI factor deficit Severity varies due to level of active clotting factor (<1 %- severe)